Form 4: IO Biotech Director David V. Smith Granted 35,144 Stock Options

IO Biotech, Inc. Director David V. Smith was granted 35,144 stock options with an exercise price of $1.50, vesting on June 5, 2026.

Summary

• David V. Smith, a Director of IO Biotech, Inc. (IOBT), acquired 35,144 stock options on June 5, 2025.
• The stock options have an exercise price of $1.50 per share.
• These options are scheduled to vest on June 5, 2026, contingent upon Mr. Smith's continued service.
• A provision for 100% acceleration of vesting exists upon a change of control.
• The options are set to expire on June 5, 2035.
• Following this transaction, Mr. Smith directly beneficially owns 35,144 derivative securities.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice that aligns the director's financial interests with the long-term performance of the company's stock. It signals continued commitment from the director, which is mildly positive for investor confidence.

Positives

• The grant of stock options to Director David V. Smith aligns his financial interests with those of the shareholders, as the options gain value only if the company's stock price increases above the exercise price.
• The vesting schedule encourages long-term commitment and continued service from the director, fostering stability in leadership.

Negatives

• While not an immediate negative, the future exercise of these options could lead to a minor dilution of existing shareholders' equity if new shares are issued upon exercise.

Risks

• The value of the stock options is contingent on the future performance of IO Biotech's common stock; if the stock price does not exceed the $1.50 exercise price, the options may expire worthless.
• The vesting of the options is subject to Mr. Smith's continued service through the applicable vesting date, meaning the options could be forfeited if his service terminates prematurely, unless a change of control event occurs.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future financial performance or strategic direction beyond the terms of the option grant.

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology and broader corporate sectors. They are widely used to incentivize long-term performance and align the interests of key personnel with those of shareholders. This specific grant to a director is a standard practice for attracting and retaining talent in competitive industries like biotech.

Comparison to Industry Standards

• This equity grant to a director is a standard compensation practice within the industry.
• The structure of the grant, including the exercise price, vesting schedule, and change of control acceleration, is typical for such compensation in the biotechnology sector.
• The document does not provide sufficient information to compare the specific grant size (35,144 options) to industry benchmarks or specific comparable companies' compensation practices.

Related Party Transactions

• This transaction involves an equity grant from IO Biotech, Inc. to David V. Smith, a director, which is a common form of compensation and an insider transaction.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making. There is a minor potential for future dilution if the options are exercised and new shares are issued.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• The granted options will vest on June 5, 2026, provided the director continues his service.
• The director may choose to exercise the options at any time after vesting and before the expiration date, assuming the company's stock price is above the exercise price.

Key Dates

Keywords

IO Biotech, IOBT, Form 4, SEC filing, insider transaction, stock options, director compensation, equity grant, David V. Smith, beneficial ownership, vesting, change of control